Status:
COMPLETED
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Conditions:
Erosive Esophagitis
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
To evaluate the healing rate and safety of Lafutidine in erosive esophagitis
Eligibility Criteria
Inclusion
- Patients who had symptoms of heartburn with a diagnosis of grade A to D reflux esophagitis according to the Los Angeles classification
Exclusion
- Gastric or duodenal ulcers (excluding ulcer scars)
- Concurrent presence of Barrett's esophagus
- A history of a poor response to H2RA or PPI given in the recommended dose for 8 weeks
- Other conditions considered by the attending physician to potentially affect the assessment of efficacy and safety
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
495 Patients enrolled
Trial Details
Trial ID
NCT01499368
Start Date
November 1 2011
End Date
November 1 2012
Last Update
January 15 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.